MARKET

ALNY

ALNY

Alnylam Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

160.42
+0.42
+0.26%
After Hours: 162.00 +1.58 +0.98% 17:37 07/08 EDT
OPEN
159.62
PREV CLOSE
160.00
HIGH
162.57
LOW
156.99
VOLUME
851.80K
TURNOVER
--
52 WEEK HIGH
164.09
52 WEEK LOW
69.11
MARKET CAP
18.42B
P/E (TTM)
-19.9851
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 22 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ALNY stock price target is 155.57 with a high estimate of 202.00 and a low estimate of 74.00.

EPS

ALNY News

More
Alnylam inks deal to commercialize RNAi drugs in Middle East
Alnylam Pharmaceuticals (NASDAQ:ALNY) and Taiba Middle East, a rare disease company based in the UAE, have formed a Distribution Agreement for both Onpattr
seekingalpha · 14h ago
Alnylam Pharmaceuticals and Taiba Group Partner to Commercialize RNAi Therapeutics in the Gulf States
Business Wire · 18h ago
Alnylam Pharma partners with Taiba Group to commercialize RNAi therapeutics in Gulf states
Seeking Alpha - Article · 19h ago
Alnylam Pharmaceuticals And Taiba Group Partner To Commercialize RNAi Therapeutics In The Gulf States
ZUG, Switzerland & DUBAI, United Arab Emirates--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, and taiba Middle East, a leading rare disease company based in the
Benzinga · 19h ago
The Daily Biotech Pulse: Intersect ENT Jumps On M&A Speculation, VIVUS Files For Bankruptcy
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7)
Benzinga · 20h ago
Alnylam Pharma Poised to Shoot Higher
TheStreet.com · 07/01 16:48
FOCUS-From Parkinson's to peanut allergy, pandemic puts brakes on new drugs
Reuters · 07/01 12:00
Heavy upside, catalysts ahead in liver disease space for Needham
Seeking Alpha - Article · 06/30 21:52

Industry

Biotechnology & Medical Research
+1.13%
Pharmaceuticals & Medical Research
+0.50%

Hot Stocks

Symbol
Price
%Change

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections.
More

Webull offers kinds of Alnylam Pharmaceuticals, Inc. stock information, including NASDAQ:ALNY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALNY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALNY stock methods without spending real money on the virtual paper trading platform.